Abingdon Health Plc engages in the development, manufacture, and distribution of diagnostic devices worldwide. The company offers AbC-19 Rapid Test, a COVID-19 IgG rapid antibody test; nucleic acid lateral flow immunoassays; PCRD and PCRD FLEX, nucleic acid lateral flow tests used for rapid readouts post isothermal amplification; Abingdon Simply Test, a range of self-tests; and 2019-nCoV Antigen Test, a rapid lateral flow test for the qualitative detection of antigens to SARS-CoV-2. It also provides AppDx, a customizable image capturing technology that transforms a smartphone into a self-sufficient and standalone lateral-flow reader. In addition, the company provides contract manufacturing, nucleic acid lateral flow test customization, and lateral flow development and manufacturing services. Further, it provides consultancy services to businesses in the healthcare technology sector. The company has a collaboration and co-marketing agreement with Abcam plc. Abingdon Health Plc was incorporated in 2008 and is headquartered in York, the United Kingdom.